In contrast, an admixed formulation of E7 oligomers with CpG-loaded VLPs was sufficient to induce optimal CD4+ and CD8+ T cell responses that proved to be protective as a therapeutic vaccine when tested in an HPV tumor model. This evidence concerns the gene CD8A and neoplasm.